NICE guideline “Ectopic pregnancy and miscarriage”: new changes and importance for the clinicist
The purpose of this publication is to summarize the current data on the effectiveness of progestogens in patients with threatened miscarriage (vaginal bleeding in the first trimester of pregnancy) and to review the updated UK National Institute for Health and Care Excel (NICE) clinical guidelines on...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Publishing House TRILIST
2021-12-01
|
| Series: | Репродуктивная эндокринология |
| Subjects: | |
| Online Access: | http://reproduct-endo.com/article/view/249799 |
| _version_ | 1818750121412657152 |
|---|---|
| author | - - |
| author_facet | - - |
| author_sort | - - |
| collection | DOAJ |
| description | The purpose of this publication is to summarize the current data on the effectiveness of progestogens in patients with threatened miscarriage (vaginal bleeding in the first trimester of pregnancy) and to review the updated UK National Institute for Health and Care Excel (NICE) clinical guidelines on ectopic pregnancy and miscarriage.
In accordance with the opinion of the Cochrane Society experts and the updated NICE clinical guidelines for 2021, vaginal progesterone at a dose of 800 mg/day is the only intervention that has been shown to be effective in increasing live births compared to placebo for women with one or more previous miscarriages and early vaginal bleeding (relative risk 1.08, 95% confidence interval 1.02–1.15, high certainty evidence). Upon confirmation of fetal heartbeat, this treatment should be extended until 16 weeks of gestation.
There is still uncertainty over the effectiveness and safety of alternative progestogen treatments (as dydrogesterone) for threatened and recurrent miscarriage. There is also no evidence of benefit of any other preparations or doses of progesterone in patients at risk of miscarriage. |
| first_indexed | 2024-12-18T04:14:38Z |
| format | Article |
| id | doaj.art-90d654a466344e65a06028b1a09bb0dc |
| institution | Directory Open Access Journal |
| issn | 2309-4117 2411-1295 |
| language | English |
| last_indexed | 2024-12-18T04:14:38Z |
| publishDate | 2021-12-01 |
| publisher | Publishing House TRILIST |
| record_format | Article |
| series | Репродуктивная эндокринология |
| spelling | doaj.art-90d654a466344e65a06028b1a09bb0dc2022-12-21T21:21:23ZengPublishing House TRILISTРепродуктивная эндокринология2309-41172411-12952021-12-0162485210.18370/2309-4117.2021.62.48-52287653NICE guideline “Ectopic pregnancy and miscarriage”: new changes and importance for the clinicist- -The purpose of this publication is to summarize the current data on the effectiveness of progestogens in patients with threatened miscarriage (vaginal bleeding in the first trimester of pregnancy) and to review the updated UK National Institute for Health and Care Excel (NICE) clinical guidelines on ectopic pregnancy and miscarriage. In accordance with the opinion of the Cochrane Society experts and the updated NICE clinical guidelines for 2021, vaginal progesterone at a dose of 800 mg/day is the only intervention that has been shown to be effective in increasing live births compared to placebo for women with one or more previous miscarriages and early vaginal bleeding (relative risk 1.08, 95% confidence interval 1.02–1.15, high certainty evidence). Upon confirmation of fetal heartbeat, this treatment should be extended until 16 weeks of gestation. There is still uncertainty over the effectiveness and safety of alternative progestogen treatments (as dydrogesterone) for threatened and recurrent miscarriage. There is also no evidence of benefit of any other preparations or doses of progesterone in patients at risk of miscarriage.http://reproduct-endo.com/article/view/249799uk national institute for health and care excellenceclinical guidelinesmiscarriageprogesterone |
| spellingShingle | - - NICE guideline “Ectopic pregnancy and miscarriage”: new changes and importance for the clinicist Репродуктивная эндокринология uk national institute for health and care excellence clinical guidelines miscarriage progesterone |
| title | NICE guideline “Ectopic pregnancy and miscarriage”: new changes and importance for the clinicist |
| title_full | NICE guideline “Ectopic pregnancy and miscarriage”: new changes and importance for the clinicist |
| title_fullStr | NICE guideline “Ectopic pregnancy and miscarriage”: new changes and importance for the clinicist |
| title_full_unstemmed | NICE guideline “Ectopic pregnancy and miscarriage”: new changes and importance for the clinicist |
| title_short | NICE guideline “Ectopic pregnancy and miscarriage”: new changes and importance for the clinicist |
| title_sort | nice guideline ectopic pregnancy and miscarriage new changes and importance for the clinicist |
| topic | uk national institute for health and care excellence clinical guidelines miscarriage progesterone |
| url | http://reproduct-endo.com/article/view/249799 |
| work_keys_str_mv | AT niceguidelineectopicpregnancyandmiscarriagenewchangesandimportancefortheclinicist |